(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors - 2JFK's granddaughter reveals terminal cancer diagnosis, criticizes cousin RFK Jr.
- 3Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- 46 Vehicle Rental Administrations: Pick Your Ideal Ride
- 5Significant Elements to Consider Prior to Applying for a Mastercard: 6 Vital Contemplations
- Pick Your Number one breakfast food
- Surging measles cases are 'fire alarm' warning that other diseases could be next
- One of the best meteor showers of the year peaks at the worst possible time this week
- Pick Your Favored kind of sandwich
- From Loner to Force to be reckoned with: Individual Accounts of Change
- Five held on suspicion of planning attack on German Christmas market
- Palestinians forced from West Bank refugee camps left in limbo as Israeli demolitions go on
- NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- Picking the Right Home Machines: A Commonsense Aide
